Invention Grant
- Patent Title: Bispecific T cell activating antigen binding molecules
-
Application No.: US15655689Application Date: 2017-07-20
-
Publication No.: US11459404B2Publication Date: 2022-10-04
- Inventor: Marina Bacac , Peter Bruenker , Christiane Neumann , Christian Klein , Ekkehard Moessner , Pablo Umana , Tina Weinzierl
- Applicant: Roche Glycart AG
- Applicant Address: CH Schlieren
- Assignee: Roche Glycart AG
- Current Assignee: Roche Glycart AG
- Current Assignee Address: CH Schlieren
- Agency: Clark & Elbing LLP
- Agent Karen L. Elbing
- Priority: EP13156674 20130226
- Main IPC: C07K16/46
- IPC: C07K16/46 ; C07K16/28 ; C07K16/32 ; C07K16/30 ; A61K39/00
Abstract:
The present invention generally relates to bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
Public/Granted literature
- US20180086849A1 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES Public/Granted day:2018-03-29
Information query
